Clinical Trials Logo

Hepatitis D, Chronic clinical trials

View clinical trials related to Hepatitis D, Chronic.

Filter by:

NCT ID: NCT04166266 Recruiting - Clinical trials for Hepatitis B, Chronic

Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic HBV/HDV Co-infection

BuleDelta
Start date: February 19, 2020
Phase:
Study type: Observational

This is a prospective, multicentric, non comparative study, with a retrospective data collection aiming at evaluating the efficacy and safety of bulevirtide in patients with chronic HBV/HDV co-infection with severe fibrosis injuries, or moderate fibrosis injuries associated with persistent increase of ALT.

NCT ID: NCT03099278 Recruiting - Chronic Hepatitis D Clinical Trials

Ezetimibe for Patients With Chronic Hepatitis D

Start date: January 2017
Phase: Phase 2
Study type: Interventional

Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with Ezetimibe may lead to decline in hepatitis D virus levels. The aim of the study is to evaluate the utility of Ezetimibe in patients with chronic HDV infection

NCT ID: NCT00117533 Recruiting - Chronic Hepatitis B Clinical Trials

Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta

Start date: September 2005
Phase: Phase 4
Study type: Interventional

The treatment of choice for chronic hepatitis D is uncertain. The investigators hypothesize that pegylated interferon (IFN) alfa-2b in combination with ribavirin (RBV) may be effective in the treatment of chronic hepatitis D patients who are also infected by hepatitis B virus (HBV). The purpose of this study is to test this hypothesis. The investigators will use pegylated IFN alfa-2b in combination with RBV for the treatment of patients with dual chronic hepatitis D virus (HDV) and HBV infection. A 24-week course of combination therapy pegylated IFN+RBV will be used.